Te Ahumairangi Investment Management Ltd Grows Stock Position in DaVita Inc. $DVA

Te Ahumairangi Investment Management Ltd increased its position in shares of DaVita Inc. (NYSE:DVA) by 15.3% during the 4th quarter, Holdings Channel reports. The institutional investor owned 78,973 shares of the company’s stock after purchasing an additional 10,507 shares during the quarter. DaVita comprises about 1.6% of Te Ahumairangi Investment Management Ltd’s holdings, making the stock its 16th largest position. Te Ahumairangi Investment Management Ltd’s holdings in DaVita were worth $8,972,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in DVA. NewEdge Advisors LLC raised its position in shares of DaVita by 20.8% during the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after buying an additional 88 shares during the period. Goldman Sachs Group Inc. raised its position in DaVita by 19.1% in the first quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock valued at $27,403,000 after purchasing an additional 28,739 shares during the period. Cerity Partners LLC raised its position in DaVita by 7.0% in the second quarter. Cerity Partners LLC now owns 2,638 shares of the company’s stock valued at $376,000 after purchasing an additional 172 shares during the period. Bank of Nova Scotia raised its position in DaVita by 3.8% in the second quarter. Bank of Nova Scotia now owns 4,813 shares of the company’s stock valued at $686,000 after purchasing an additional 176 shares during the period. Finally, Natixis raised its position in DaVita by 80.9% in the second quarter. Natixis now owns 7,297 shares of the company’s stock valued at $1,039,000 after purchasing an additional 3,264 shares during the period. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

Shares of DVA opened at $203.72 on Friday. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $205.42. The company has a market capitalization of $13.08 billion, a price-to-earnings ratio of 18.90, a price-to-earnings-growth ratio of 0.65 and a beta of 0.91. The firm has a 50-day simple moving average of $174.98 and a 200-day simple moving average of $145.65.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The company had revenue of $3.42 billion during the quarter, compared to analysts’ expectations of $3.36 billion. During the same period last year, the firm earned $2.00 EPS. The firm’s revenue for the quarter was up 6.0% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities research analysts forecast that DaVita Inc. will post 15.07 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on DVA. UBS Group boosted their target price on DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of DaVita in a research report on Monday. Truist Financial raised their price objective on DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a report on Friday, May 8th. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Finally, TD Cowen raised their price objective on DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $199.17.

Insider Activity at DaVita

In other news, CFO Joel Ackerman sold 51,471 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the completion of the sale, the chief financial officer owned 132,434 shares in the company, valued at $25,440,571.40. This represents a 27.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.50% of the stock is owned by company insiders.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.